

# CITATION REPORT

List of articles citing

The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy

DOI: 10.1001/jamaophthalmol.2014.3459  
JAMA Ophthalmology, 2014, 132, 1453-60.

**Source:** <https://exaly.com/paper-pdf/58444457/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
442	Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. <b>2015</b> , 67, 2176-84		87
441	Advanced hydroxychloroquine maculopathy against medical advice. <b>2015</b> , 2,		
440	Hydroxychloroquine Retinopathy. <b>2015</b> , 22, 140		
439	Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral fovea. <b>2015</b> , 56, 3415-26		61
438	A Clinician's Guide to Diagnosing and Managing Psoriatic Arthritis. <b>2015</b> , 1, 9-25		
437	Unusual Fundus Autofluorescence Appearance in a Patient with Hydroxychloroquine Retinal Toxicity. <b>2015</b> , 6, 186-90		1
436	A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye. <b>2015</b> , 49, 317-26		77
435	Hydroxychloroquine and the retina. <b>2015</b> , 313, 847-8		8
434	Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy. <b>2015</b> , 160, 799-805.e1		43
433	Pericentral hydroxychloroquine retinopathy in Korean patients. <b>2015</b> , 122, 1252-6		46
432	Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy). <b>2015</b> , 15, 18		21
431	Hydroxychloroquine screening practice patterns within a large multispecialty ophthalmic practice. <b>2015</b> , 160, 561-568.e2		12
430	Systemic lupus erythematosus: review of synthetic drugs. <b>2015</b> , 16, 2793-806		14
429	Systemic Lupus Erythematosus and the Eye. <b>2016</b> , 431-439		
428	Optical coherence tomography based microangiography findings in hydroxychloroquine toxicity. <b>2016</b> , 6, 178-83		8
427	Value of Antimalarial Drugs in the Treatment of Lupus. <b>2016</b> , 515-520		
426	Analysis of Clinical Factors Associated with Retinal Morphological Changes in Patients with Primary Sjögren's Syndrome. <b>2016</b> , 11, e0157995		6

425	Immunomodulators in SLE: Clinical evidence and immunologic actions. <b>2016</b> , 74, 73-84	54
424	The Demise of the Bull's Eye (Screening for Hydroxychloroquine Retinopathy). <b>2016</b> , 36, 1803-5	4
423	Enfermedades autoinmunes sistémicas en atención primaria. <b>2016</b> , 23, 513-527	
422	Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease. <b>2016</b> , 64, 908-10	12
421	Anti-malarials: Are There Benefits Beyond Mild Disease?. <b>2016</b> , 2, 1-12	5
420	Hydroxychloroquine-Induced Retinal Toxicity. <b>2016</b> , 233, 514-6	2
419	Manual of Retinal Diseases. <b>2016</b> ,	1
418	[Adverse Drug Reactions in Ophthalmology--Update 2015/2016]. <b>2016</b> , 233, 203-16; quiz 217-99	1
417	Chloroquine/Hydroxychloroquine Toxicity. <b>2016</b> , 429-432	
416	Reply. <b>2016</b> , 170, 239-240	
415	Why targeted therapies are necessary for systemic lupus erythematosus. <b>2016</b> , 25, 1070-9	17
414	Signs of hydroxychloroquine toxicity in a patient with rhegmatogenous retinal detachment. <b>2016</b> , 91, 450-452	
413	The Prevalence of Hydroxychloroquine Retinopathy and Toxic Dosing, and the Role of the Ophthalmologist in Reducing Both. <b>2016</b> , 170, 240	7
412	Impact of an Electronic Decision Support Tool on Hydroxychloroquine Screening. <b>2016</b> , 123, 2433-2435	3
411	Retinopathy in the Era of Routine Hydroxychloroquine Monitoring. <b>2016</b> , 43, 1254	1
410	Dr. Durcan, et al reply. <b>2016</b> , 43, 1255	
409	LOSS OF EXTERNAL LIMITING MEMBRANE INTEGRITY PREDICTS PROGRESSION OF HYDROXYCHLOROQUINE RETINAL TOXICITY AFTER DRUG DISCONTINUATION. <b>2016</b> , 36, 1951-1957	9
408	AIMING FOR THE BULL'S EYE: The Cost-Utility of Screening for Hydroxychloroquine Retinopathy. <b>2016</b> , 36, 1958-63	1

407	New Perspectives in Rheumatology: Avoiding Antimalarial Toxicity. <b>2016</b> , 68, 1805-9		2
406	Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach. <b>2016</b> , 23, 67-75		32
405	Signs of hydroxychloroquine toxicity in a patient with rhegmatogenous retinal detachment. <b>2016</b> , 91, 450-2		1
404	Unerwünschte Arzneimittelwirkungen in der Augenheilkunde: Update 2015/2016. <b>2016</b> , 6, 15-29		
403	Analysis of Inner and Outer Retinal Thickness in Patients Using Hydroxychloroquine Prior to Development of Retinopathy. <i>JAMA Ophthalmology</i> , <b>2016</b> , 134, 511-519	3.9	16
402	Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). <b>2016</b> , 123, 1386-94		596
401	The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study. <b>2016</b> , 74, 693-9.e3		44
400	Adherence to Hydroxychloroquine Dosing Guidelines by Rheumatologists: An Electronic Medical Record-Based Study in an Integrated Health Care System. <b>2017</b> , 124, 604-608		12
399	Hydroxychloroquine retinopathy. <b>2017</b> , 31, 828-845		99
398	Hydroxychloroquine retinopathy: an emerging problem. <b>2017</b> , 31, 972-976		15
397	Effect of axial length on full-field and multifocal electroretinograms. <b>2017</b> , 100, 668-675		14
396	ERG and other discriminators between advanced hydroxychloroquine retinopathy and retinitis pigmentosa. <b>2017</b> , 134, 175-183		11
395	The gathering storm: hydroxychloroquine retinopathy screening in the U.K. <b>2017</b> , 176, 1420-1421		4
394	Hydroxychloroquine toxicity and aromatase inhibitors. <b>2017</b> , 177, 882		4
393	Reply. <b>2017</b> , 124, e29-e30		
392	Screening for hydroxychloroquine retinal toxicity: Current recommendations. <b>2017</b> , 14, 27-30		
391	Paracentral acute middle maculopathy as a finding in patients with severe vision loss following phacoemulsification cataract surgery. <b>2017</b> , 45, 598-605		21
390	Updated recommendations on the use of hydroxychloroquine in dermatologic practice. <b>2017</b> , 76, 1176-1182		29

389	Value of Microperimetry in Detecting Early Retinal Toxicity of Hydroxychloroquine in Children with Juvenile Systemic Lupus Erythematosus. <b>2017</b> , 237, 180-184	5
388	[Update on recommendations for screening for hydroxychloroquine retinopathy]. <b>2017</b> , 40, 793-800	9
387	SAT0255 A randomized, placebo-controlled, double-blind, ascending-dose, safety study of CC-220 in subjects with systemic lupus erythematosus. <b>2017</b> ,	3
386	Choroidal Thinning Associated With Hydroxychloroquine Retinopathy. <b>2017</b> , 183, 56-64	24
385	Risk of Retinal Toxicity in Longterm Users of Hydroxychloroquine. <b>2017</b> , 44, 1674-1679	31
384	Cholesterol-modified Hydroxychloroquine-loaded Nanocarriers in Bleomycin-induced Pulmonary Fibrosis. <b>2017</b> , 7, 10737	19
383	Recomendações da Sociedade Brasileira de Reumatologia para diagnóstico e tratamento da febre chikungunya. Parte 2 - Tratamento. <b>2017</b> , 57, 438-451	20
382	Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety. <b>2017</b> , 37, 1611-16186	
381	Modern management of antimalarial usage and retinopathy. <b>2017</b> , 29, 143-144	2
380	Recommendations of the Brazilian Society of Rheumatology for the diagnosis and treatment of chikungunya fever. Part 2 - Treatment. <b>2017</b> , 57 Suppl 2, 438-451	9
379	PANRETINAL DEGENERATION ASSOCIATED WITH LONG-TERM HYDROXYCHLOROQUINE USE AND HETEROZYGOUS USH2A MUTATION. <b>2017</b> , 11 Suppl 1, S77-S80	4
378	Pharmacotherapy Pearls for the Geriatrician: Focus on Oral Disease-Modifying Antirheumatic Drugs Including Newer Agents. <b>2017</b> , 33, 1-15	4
377	S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). <b>2017</b> , 31, 389-404	75
376	Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. <b>2017</b> , 13, 35-41	21
375	Hydroxychloroquine-induced retinopathy in a 57-year-old woman. <b>2017</b> , 189, E69-E72	1
374	Implementation of recommendations for the screening of hydroxychloroquine retinopathy: poor adherence of rheumatologists and ophthalmologists. <b>2017</b> , 26, 277-281	10
373	Hydroxychloroquine prescribing and monitoring practices among Irish dermatologists and rheumatologists. <b>2017</b> , 176, 831-832	3
372	Research progress of hydroxychloroquine and autophagy inhibitors on cancer. <b>2017</b> , 79, 287-294	77

371	Curvilinear bodies are associated with adverse effects on muscle function but not with hydroxychloroquine dosing. <b>2017</b> , 36, 689-693	5
370	Desirable and Adverse Effects of Antiinflammatory Agents on the Heart. <b>2017</b> , 617-643	0
369	Frequency and Clinical Characteristics of Hydroxychloroquine Retinopathy in Korean Patients with Rheumatologic Diseases. <b>2017</b> , 32, 522-527	13
368	The Eye and Rheumatic Diseases. <b>2017</b> , 645-653	2
367	Requirement for retinal screening in patients taking hydroxychloroquine and chloroquine. <b>2018</b> , 68, 120	1
366	Macular sensitivities measured by microperimetry in patients on hydroxychloroquine treatment. <b>2018</b> , 37, 275-280	1
365	Retinopathy from hydroxychloroquine is not related to lupus or rheumatoid arthritis. <b>2018</b> , 136, 93-94	0
364	Response to risk of hydroxychloroquine retinopathy is not related to systemic lupus erythematosus or rheumatoid arthritis. <b>2018</b> , 136, 95-96	
363	Effects of Selective Serotonin Reuptake Inhibitors on Macular Ganglion Cell Complex Thickness and Peripapillary Retinal Nerve Fiber Layer Thickness. <b>2018</b> , 43, 547-552	7
362	Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus. <b>2018</b> , 48, 205-213	37
361	Solving the Hydroxychloroquine Dosing Dilemma With a Smartphone App. <i>JAMA Ophthalmology</i> , <b>2018</b> , 136, 218-219	3.9 5
360	Use of En Face Optical Coherence Tomography in a Case of Hydroxychloroquine Retinal Toxicity. <b>2018</b> , 2, 51-57	
359	Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016. <b>2018</b> , 37, 1853-1859	6
358	Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. <b>2018</b> , 30, 249-255	33
357	Hydroxychloroquine Toxicity. <b>2018</b> , 68-71	
356	Systemic lupus erythematosus and ocular involvement: an overview. <b>2018</b> , 18, 135-149	57
355	Toxicidade retiniana pela hidroxiclороquina: frequência em um ambulatório de Oftalmologia. <b>2018</b> , 77,	
354	Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. <b>2018</b> , 14, 693-703	99

353	Peripapillary Retinal Nerve Fiber Layer Thicknesses Did Not Change in Long-term Hydroxychloroquine Users. <b>2018</b> , 32, 459-469	4
352	An audit of the use of hydroxychloroquine in rheumatology clinics. <b>2018</b> , 2, rky013	3
351	Hydroxychloroquine and risk of development of cancers: a nationwide population-based cohort study. <b>2018</b> , 14, 1435-1443	2
350	Systemic scleroderma and lupus panniculitis with atypical clinical features: A case report and comprehensive review. <b>2018</b> , 4, 789-793	3
349	Hydroxychloroquine Retinopathy Update. <b>2018</b> , 25, 153	
348	Somatotype, the risk of hydroxychloroquine retinopathy, and safe daily dosing guidelines. <b>2018</b> , 12, 811-818	13
347	Early morpho-functional changes in patients treated with hydroxychloroquine: a prospective cohort study. <b>2018</b> , 256, 2201-2210	6
346	Joint recommendations for retinal screening in long-term users of hydroxychloroquine and chloroquine in the United Kingdom, 2018. <b>2018</b> , 179, 995-996	4
345	Case Report: Hydroxychloroquine Retinopathy. <b>2018</b> , 95, 545-549	2
344	Using hydroxychloroquine and protecting the retina. <b>2018</b> , 27, 1399-1401	1
343	Atypical fibroxanthoma in a young female patient with systemic lupus erythematosus: A case report and literature review. <b>2018</b> , 36, 214-217	
342	Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort. <b>2018</b> , 27, 1616-1623	12
341	Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors. <b>2018</b> , 44, 371-391	11
340	Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. <b>2018</b> , 20, 133	26
339	Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. <b>2018</b> , 38, 653-671	152
338	Hydroxychloroquine retinal toxicity in two patients with dermatological conditions. <b>2018</b> , 59, e266-e268	4
337	34 Drug and Light Ocular Toxicity. <b>2018</b> ,	
336	[Prevalence of hydroxychloroquine-induced side-effects in dermatology patients: A retrospective survey of 102 patients]. <b>2018</b> , 145, 395-404	11

335	Evidence for the Detection of Subclinical Retinal Involvement in Systemic Lupus Erythematosus and Sjögren Syndrome: A Potential Association with Therapies. <b>2018</b> , 177, 45-56	15
334	The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. <b>2018</b> , 32, 1168-1173	26
333	Autophagy Inhibition and Chemosensitization in Cancer Therapy. <b>2019</b> , 259-273	2
332	ACCELERATED ONSET OF RETINAL TOXICITY FROM HYDROXYCHLOROQUINE USE WITH CONCOMITANT BREAST CANCER THERAPY. <b>2019</b> , 13, 98-102	2
331	Visual Loss: Retinal Disorders of Neuro-Ophthalmic Interest. <b>2019</b> , 53-99	1
330	Hydroxychloroquine During Cancer Therapy. <b>2019</b> , 13, 95-97	1
329	The 2016 American Academy of Ophthalmology Recommendations for Hydroxychloroquine Dosing Give Accurate Advice for All Patients. <b>2019</b> , 3, 807-808	3
328	Imaging of Hydroxychloroquine Toxicity with Fluorescence Lifetime Imaging Ophthalmoscopy. <b>2019</b> , 3, 814-825	9
327	Enhancement of Adeno-Associated Virus-Mediated Gene Therapy Using Hydroxychloroquine in Murine and Human Tissues. <b>2019</b> , 14, 77-89	14
326	Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery. <b>2019</b> , 6, e000335	1
325	Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate?. <b>2019</b> , 45, 359-367	6
324	Diagnostic pitfalls and laboratory test interference after hydroxychloroquine intoxication: A case report. <b>2019</b> , 6, 1040-1046	18
323	Lupus erythematosus tumidus: clinical perspectives. <b>2019</b> , 12, 707-719	9
322	Hypertrophic cardiomyopathy in a lupus patient: a case of hydroxychloroquine cardiotoxicity. <b>2019</b> , 6, 1326-1330	5
321	The 2016 American Academy of Ophthalmology Hydroxychloroquine Dosing Guidelines For Short, Obese Patients. <b>2019</b> , 3, 809-813	4
320	Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. <b>2019</b> , 209, 108274	39
319	Targeting Autophagy for Cancer Treatment and Tumor Chemosensitization. <b>2019</b> , 11,	85
318	Take a look at the eyes in Systemic Lupus Erythematosus: A novel point of view. <b>2019</b> , 18, 247-254	17



317	Comment on: Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine. <b>2019</b> , 3, rkz041	1
316	Current screening practice in patients under long-term hydroxychloroquine medication in Taiwan: A nationwide population-based cohort study. <b>2019</b> , 98, e15122	3
315	Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review. <b>2019</b> , 79, 1199-1215	14
314	Automated Segmentation Measurements of the Outer Nuclear Layer in Determining Cases of Hydroxychloroquine Toxicity: A Retrospective Study. <b>2019</b> , 3, 135-144	2
313	Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine. <b>2019</b> , 3, rkz009	7
312	Management strategies and future directions for systemic lupus erythematosus in adults. <b>2019</b> , 393, 2332-2343	132
311	Fluorescence Lifetimes in Patients With Hydroxychloroquine Retinopathy. <b>2019</b> , 60, 2165-2172	8
310	The Diagnostic Utility of Multifocal Electroretinography in Detecting Chloroquine and Hydroxychloroquine Retinal Toxicity. <b>2019</b> , 206, 132-139	14
309	How to set up a Hydroxychloroquine Retinopathy Screening Service. <b>2019</b> , 33, 1679-1682	7
308	MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study. <b>2019</b> , 39, 485-491	4
307	Effect of Hydroxychloroquine and Anti-BDCA2 mAb Treatment on pDC IFN $\beta$ Production From Patients Affected With Cutaneous Lupus Erythematosus. <b>2019</b> , 10, 275	19
306	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <b>2019</b> , 78, 736-745	628
305	Evaluation of photoreceptor outer segment length in hydroxychloroquine users. <b>2019</b> , 33, 1321-1326	3
304	Changing paradigms in the treatment of systemic lupus erythematosus. <b>2019</b> , 6, e000310	31
303	Association of Crystalline Retinopathy With Anastrozole. <i>JAMA Ophthalmology</i> , <b>2019</b> , 137, 581-582	3.9 3
302	Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus. <b>2019</b> , 28, 555-559	10
301	Update on the treatment and outcome of systemic lupus erythematosus in children. <b>2019</b> , 31, 464-470	12
300	SEQUENTIAL CHANGES IN HYDROXYCHLOROQUINE RETINOPATHY UP TO 20 YEARS AFTER STOPPING THE DRUG: Implications for Mild Versus Severe Toxicity. <b>2019</b> , 39, 492-501	15

299	Screening for Hydroxychloroquine Retinopathy-Can We Do Better?. <b>2019</b> , 39, 423-425	2
298	Systemic lupus erythematosus in pregnancy: high risk, high reward. <b>2019</b> , 31, 120-126	5
297	Wide field retinal imaging and the detection of drug associated retinal toxicity. <b>2019</b> , 5, 26	7
296	Antimalarial Medications. <b>2019</b> , 650-660	
295	Rheumatoid Arthritis. <b>2019</b> , 170, ITC1-ITC16	193
294	Hydroxychloroquine sulphate therapy of erosive oral lichen planus. <b>2019</b> , 60, e109-e112	5
293	Evaluation of toxic retinopathy caused by antimalarial medications with spectral domain optical coherence tomography. <b>2019</b> , 82, 12-17	8
292	Connective Tissue Disease: Current Concepts. <b>2019</b> , 37, 37-48	4
291	Structural and Functional Characterization of the Retinal Effects of Hydroxychloroquine Treatment in Healthy Eyes. <b>2019</b> , 241, 226-233	2
290	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations. <b>2019</b> , 139, 270-276	12
289	Hydroxychloroquine dosing in systemic lupus erythematosus: response to 'Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis by Costedoat-Chalumeau. <b>2020</b> , 79, e91	6
288	Patients opinion and adherence to antimalarials in lupus erythematosus and rheumatoid arthritis treatment. <b>2020</b> , 31, 264-269	1
287	Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis. <b>2020</b> , 79, e90	6
286	A comprehensive, multidisciplinary, precision medicine approach to discover effective therapy for an undiagnosed, progressive, fibroinflammatory disease. <b>2020</b> , 215, 31-40	
285	An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review. <b>2020</b> , 82, 709-722	12
284	Practical Guide to Dermatology. <b>2020</b> ,	0
283	Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. <b>2020</b> , 72, 448-453	50
282	Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram in patients with rheumatic disorders. <b>2020</b> , 55, 38-44	1

281	Retinal Complications in Patients with Systemic Lupus Erythematosus Treated with Antimalarial Drugs. <b>2020</b> , 47, 553-556	6
280	[Progressive maculopathy despite discontinuation of chloroquine treatment-multimodal imaging and review of the literature]. <b>2020</b> , 117, 917-925	0
279	Hydroxychloroquine in diabetes and dyslipidaemia: primum non nocere. <b>2020</b> , 37, 1404-1405	4
278	Knowing when to use steroids, immunosuppressants or biologics for the treatment of sarcoidosis. <b>2020</b> , 14, 285-298	12
277	Hydroxychloroquine Retinopathy in the Era of Advanced Imaging Modalities. <b>2020</b> , 60, 73-83	0
276	Unique changes in the retinal microvasculature reveal subclinical retinal impairment in patients with systemic lupus erythematosus. <b>2020</b> , 129, 103957	4
275	Advanced Pericentral Hydroxychloroquine Retinopathy in an Asian Woman. <b>2020</b> , 4, 148-151	
274	Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine. <b>2020</b> , 29, 52-57	10
273	Drug interactions with antimalarial medications in older travelers: a clinical guide. <b>2020</b> , 27,	12
272	Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence. <b>2020</b> , 22, 223	5
271	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. <b>2020</b> , 216, 107672	31
270	Update on antimalarials and systemic lupus erythematosus. <b>2020</b> , 32, 572-582	6
269	Hydroxychloroquine retinal toxicity: The bull's eye in the human eye. <b>2020</b> , 21, 100818	1
268	Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. <b>2020</b> , 76, 292-302	38
267	Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy. <b>2020</b> , 21,	11
266	[Toxic retinopathies]. <b>2020</b> , 117, 1247-1266	0
265	[Therapeutic de-escalation in systemic lupus erythematosus in remission]. <b>2020</b> , 41, 795-799	0
264	Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. <b>2020</b> , 59, v69-v81	16

263	Mechanisms Underlying Potential Therapeutic Approaches for COVID-19. <b>2020</b> , 11, 1841	6
262	Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia. <b>2020</b> , 25, 497-502	2
261	LC-MS based metabolomics reveals metabolic pathway disturbance in retinal pigment epithelial cells exposed to hydroxychloroquine. <b>2020</b> , 328, 109212	3
260	Reply. <b>2020</b> , 72, 2166	
259	Pentosan Polysulfate Maculopathy-Prescribers Should Be Aware. <i>JAMA Ophthalmology</i> , <b>2020</b> , 138, 900-903	5
258	Do Hydroxychloroquine Blood Levels and Dose Identify Different Populations at Risk of Retinopathy? Comment on the Article by Petri et al. <b>2020</b> , 72, 2165-2166	
257	Hydroxychloroquine retinopathy-less than meets the eye. <b>2021</b> , 35, 2897	
256	COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. <b>2020</b> , 17, e1003252	55
255	Quantitative Fundus Autofluorescence in HCQ Retinopathy. <b>2020</b> , 61, 41	4
254	Lupus nephritis. <b>2020</b> , 6, 7	127
253	Longitudinal Retinal Changes Induced by Hydroxychloroquine in Eyes without Retinal Toxicity. <b>2021</b> , 64, 290-296	1
252	Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2. <b>2020</b> , 6, 1-9	37
251	Quantitative Fundus Autofluorescence in Systemic Chloroquine/Hydroxychloroquine Therapy. <b>2020</b> , 9, 42	6
250	Spectral-Domain Optical Coherence Tomography Is More Sensitive for Hydroxychloroquine-Related Structural Abnormalities Than Short-Wavelength and Near-Infrared Autofluorescence. <b>2020</b> , 9, 8	3
249	Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. <b>2020</b> , 22, 191	8
248	Sicherheitsmanagement der Therapie mit Antimalariamitteln: was bedeuten die neuen Empfehlungen für die Praxis?. <b>2020</b> , 45, 314-318	
247	Dendritic cells as predictive markers of responsiveness to hydroxychloroquine treatment in primary cicatricial alopecia patients. <b>2020</b> , 33, e14509	
246	Adverse drug reactions associated with treatment in patients with chronic rheumatic diseases in childhood: a retrospective real life review of a single center cohort. <b>2020</b> , 60, 53	3

245	Manifestaciones cutáneas del lupus eritematoso. <b>2020</b> , 54, 1-17	
244	Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease. <b>2020</b> , 21, 450	0
243	Rheumatologists' perspective on hydroxychloroquine guidelines. <b>2020</b> , 7,	1
242	COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?. <b>2020</b> , 216, A1-A2	13
241	A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. <b>2020</b> , 254, 117775	24
240	Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS-evaluation of whole blood, plasma, and serum as sample matrices. <b>2020</b> , 22, 125	13
239	Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose. <b>2020</b> , 59, 2105-2112	4
238	Keeping an Eye on Hydroxychloroquine Retinopathy. <b>2020</b> , 237, 490-492	1
237	Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis. <b>2020</b> , 29, 560-568	9
236	COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?. <b>2020</b> , 213, A3-A4	27
235	Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines. <b>2020</b> , 219, 101-106	7
234	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. <b>2020</b> , 16, 155-166	596
233	Hydroxychloroquine baseline retinopathy screening: when to refer patients? A practical approach to optimise resource use. <b>2020</b> , 34, 1305-1306	1
232	A path to the development of screening guidelines for pentosan maculopathy. <b>2020</b> , 55, 1-2	3
231	[Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search]. <b>2020</b> , 79, 186-194	6
230	Electrophysiological and SD-OCT findings in patients receiving chloroquine therapy in relation to cumulative dosage and duration of treatment. <b>2020</b> , 141, 1-14	1
229	Rheumatoid arthritis in the elderly: Characteristics and treatment considerations. <b>2020</b> , 19, 102528	16
228	Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review. <b>2020</b> , 23, 177-181	28

227	Treatment of cutaneous lupus erythematosus: current approaches and future strategies. <b>2020</b> , 32, 208-214	4
226	Current opinion on hydroxychloroquine-related retinal toxicity screening: where do we stand now?. <b>2020</b> , 29, 671-675	1
225	Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity. <b>2020</b> , 40, 387-388	21
224	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. <b>2020</b> , 111, 102468	76
223	Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing. <b>2020</b> , 108, 253-263	75
222	Genetic susceptibility to hydroxychloroquine retinal toxicity. <b>2020</b> , 41, 159-170	4
221	Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review. <b>2021</b> , 80, 1-9	13
220	Improving Hydroxychloroquine Dosing and Toxicity Screening at a Tertiary Care Ambulatory Center: A Quality Improvement Initiative. <b>2021</b> , 48, 138-144	2
219	Use of OCT Retinal Thickness Deviation Map for Hydroxychloroquine Retinopathy Screening. <b>2021</b> , 128, 110-119	6
218	Systemic lupus erythematosus and the eye. <b>2021</b> , 487-495	
217	Value of antimalarial drugs in the treatment of lupus. <b>2021</b> , 591-595	1
216	Antimalarial Agents. <b>2021</b> , 234-244.e4	1
215	Two years' experience of screening for hydroxychloroquine retinopathy. <b>2021</b> , 35, 1171-1177	2
214	Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria. <b>2021</b> , 35, 343-348	7
213	ASYMMETRIC HYDROXYCHLOROQUINE MACULAR TOXICITY WITH APHAKIC FELLOW EYE. <b>2021</b> , 15, 176-178	2
212	Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 Epidemic. <b>2021</b> , 14, 163-169	7
211	Long-Term Progression of Pericentral Hydroxychloroquine Retinopathy. <b>2021</b> , 128, 889-898	2
210	What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. <b>2021</b> , 31, 291-303	

209	Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies. <b>2021</b> , 27, 152-171	6
208	Hydroxychloroquine Retinal Toxicity and Its Association with Dosage. <b>2021</b> , 48, 150	1
207	Improving eye screening practice among pediatric rheumatology patients receiving hydroxychloroquine. <b>2021</b> , 30, 269-279	1
206	Improving ophthalmic screening for hydroxychloroquine associated retinopathy. <b>2021</b> , 16, 133-138	
205	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. <b>2021</b> , 53, 117-134	26
204	Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. <b>2021</b> , 59, 12-23	24
203	Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak. <b>2021</b> , 41, 719-725	2
202	Is optical coherence tomography angiography a useful tool in the screening of hydroxychloroquine retinopathy?. <b>2021</b> , 41, 27-33	5
201	The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients. <b>2021</b> , 30, 554-559	3
200	A review of diseases of the retina for neurologists. <b>2021</b> , 178, 1-11	2
199	Retinal thickness and microvascular alterations in the diagnosis of systemic lupus erythematosus: a new approach.. <b>2022</b> , 12, 823-837	3
198	Anti-Infectives. <b>2021</b> , 19-85	
197	Hydroxychloroquine and SARS-CoV-2 (COVID-19): An Old Problem and New Considerations in Ophthalmology. <b>2021</b> , 14, 78-81	
196	The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary. <b>2021</b> , 35, 1532-1537	4
195	Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey. <b>2021</b> , 13, 1759720X211002595	2
194	Hydroxychloroquine screening in the UK-closing the gaps. <b>2021</b> , 35, 1538-1540	0
193	Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2-3 mg/kg/day): 12-month prospective randomized controlled trial. <b>2021</b> , 40, 2745-2751	2
192	Systemic Lupus Erythematosus. <b>2021</b> , 1-15	

191	Accuracy of self-reported risk factors for hydroxychloroquine retinopathy. <b>2021</b> ,	
190	Baseline retinal testing is no longer recommended for hydroxychloroquine users in the United Kingdom. <b>2021</b> , 60, 2037-2039	
189	Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19. <b>2021</b> ,	1
188	Hydroxychloroquine Sulfate Related Hypoglycemia In A Non-Diabetic COVID-19 Patient: A Case Report and Literature Review. <b>2021</b> , 133, 548-551	3
187	Low-dose oral hydroxychloroquine led to impaired vision in a child with renal failure: Case report and literature review. <b>2021</b> , 100, e24919	3
186	Prevalence of hydroxychloroquine retinopathy with long-term use in a cohort of Indian patients with rheumatic diseases. <b>2021</b> , 41, 929-937	0
185	Screening for hydroxychloroquine retinopathy in Australia. <b>2021</b> , 214, 301-302.e1	1
184	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. <b>2021</b> ,	7
183	Diagnosis of Inherited Retinal Diseases. <b>2021</b> , 238, 249-259	6
182	Repositioned Drugs for COVID-19-the Impact on Multiple Organs. <b>2021</b> , 3, 1-18	3
181	Metabolic rerouting via SCD1 induction impacts X-linked adrenoleukodystrophy. <b>2021</b> , 131,	5
180	Treatment with chloroquine is retinotoxic in captive African penguins ( <i>Spheniscus demersus</i> ). Attenuation and recovery of electroretinographic responses. <b>2021</b> , 24, 336-345	0
179	American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. <b>2021</b> , 73, 908-911	10
178	Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities. <b>2021</b> , 41, 1189-1202	5
177	Hydroxychloroquine. 3, 33-39	
176	Ocular findings in Japanese patients with hydroxychloroquine retinopathy developing within 3 years of treatment. <b>2021</b> , 65, 472-481	2
175	SEQUENTIAL RETINAL THICKNESS ANALYSIS SHOWS HYDROXYCHLOROQUINE DAMAGE BEFORE OTHER SCREENING TECHNIQUES. <b>2021</b> , 15, 185-196	2
174	Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. <b>2021</b> , 73, 997-1004	7



173	Evaluation of optical coherence tomography angiography parameters in patients treated with Hydroxychloroquine. <b>2021</b> , 21, 209	2
172	Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. <b>2021</b> , 151, 112106	3
171	Frequency and risk factors for hydroxychloroquine retinopathy among patients with systemic lupus erythematosus. <b>2021</b> , 33, 18	
170	Implementation of a pilot teleretinal screening protocol for hydroxychloroquine retinopathy in a Los Angeles County safety net clinic. <b>2021</b> , 1357633X211018102	
169	Hydroxychloroquine: Pharmacological, physicochemical aspects and activity enhancement through experimental formulations. <b>2021</b> , 63, 102512	0
168	Targeted Delivery of Chloroquine to Plasmacytoid Dendritic Cells Enhances Inhibition of the Type I Interferon Response.	
167	Retinal toxicity caused by hydroxychloroquine in patients with systemic lupus erythematosus: A case report. <b>2021</b> , 100, e25688	0
166	Friends or Foes? An Update on Retinal Toxicities of Systemic Medications. <b>2021</b> , 52, 302-306	
165	Visual electrophysiology in the assessment of toxicity and deficiency states affecting the visual system. <b>2021</b> , 35, 2344-2353	0
164	Phytochemical add-on therapy to DMARDs therapy in rheumatoid arthritis: In vitro and in vivo bases, clinical evidence and future trends. <b>2021</b> , 169, 105618	7
163	A review on the pharmacokinetic properties and toxicity considerations for chloroquine and hydroxychloroquine to potentially treat coronavirus patients. <b>2021</b> , 1-12	2
162	Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: A retrospective multicenter cohort study of 56 patients. <b>2021</b> ,	0
161	Hydroxychloroquine Prescription Practices after 2016 American Academy of Ophthalmology Recommendations. <b>2021</b> , 128, 1112-1114	1
160	Fundus Autofluorescence and Clinical Applications. <b>2021</b> , 16, 432-461	1
159	Nanocarriers in the Delivery of Hydroxychloroquine to the Respiratory System: An Alternative to COVID-19. <b>2021</b> , 18, 583-595	4
158	A Practical Approach to the Diagnosis and Management of Classic Lichen Planopilaris. <b>2021</b> , 22, 681-692	2
157	Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Systemic Lupus Erythematosus and Rheumatoid Arthritis: Results of a Quality Improvement Initiative. <b>2021</b> , 3, 733-737	
156	Reply. <b>2021</b> ,	

155	[Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19]. <b>2021</b> ,	
154	Antimalarial-induced retinal toxicity. <b>2021</b> , 28, 132-132	0
153	Safety of long-term use of four common conventional disease modifying anti-rheumatic drugs in rheumatoid arthritis. <b>2021</b> , 51, 237-245	1
152	Hydroxychloroquine retinal toxicity- Can we do better with SD-OCT?. <b>2021</b> , 7, 457-465	
151	Deep-learning based automatic detection of ellipsoid zone loss in SD-OCT for hydroxychloroquine retinal toxicity screening. <b>2021</b> , 100060	3
150	The effect of an electronic medical record intervention on hydroxychloroquine prescribing habits and surveyed providers' opinions of the 2016 American Academy of Ophthalmology guidelines in the rheumatology and dermatology practices of an academic institutionle. <b>2021</b> , 21, 913	
149	Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. <b>2021</b> , 123, 102707	2
148	Reply. <b>2021</b> , 73, 2149-2150	1
147	First-principles DFT investigations of the vibrational spectra of chloro-quine and hydroxychloroquine.	
146	A Multidisciplinary Collaborative Approach to Retinal Toxic Effects Screening for Dermatology Patients Taking Antimalarials. <b>2021</b> , 157, 1112-1113	1
145	Engineered bio-adhesive polyhedral oligomeric silsesquioxane hybrid nanoformulation of amphotericin B for prolonged therapy of fungal keratitis. <b>2021</b> , 421, 129734	7
144	[Ophthalmic follow-up of patients treated with antimalarial drugs: Evaluation of patient attitudes regarding the change in protocol]. <b>2021</b> , 44, e493-e496	
143	Antimalarial drugs (and lupus). <b>2021</b> , 601-609	
142	Treatment Approach, Pharmacological Agents and Vaccines. <b>2021</b> , 145-162	
141	Comment on: Assessing the risk of retinopathy in indian patients using hydroxychloroquine for rheumatic and musculoskeletal diseases: A retrospective observational study. <b>2021</b> , 16, 365	
140	Kidney disease. <b>2021</b> , 471-502	
139	Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. <b>2020</b> , 59, 3807-3816	10
138	Of mice, microglia, and (wo)men: a case series and mechanistic investigation of hydroxychloroquine for complex regional pain syndrome. <b>2020</b> , 5, e841	2

137	Screening for Hydroxychloroquine Retinal Toxicity in Indian Patients. <b>2021</b> , 27, e395-e398	3
136	Delayed progression of bull's eye maculopathy. <b>2017</b> , 2017,	1
135	Ocular involvement in systemic lupus erythematosus patients: a paradigm shift based on the experience of a tertiary referral center. <b>2020</b> , 29, 283-289	6
134	A Case of Recurrent Steroid-dependent Kikuchi-Bujimoto Disease Successfully Treated with Hydroxychloroquine. <b>2017</b> , 24, 144-147	1
133	[Differential diagnosis of hydroxychloroquine-induced retinal damage]. <b>2020</b> , 136, 265-271	1
132	Beta-adrenergic agonist protects retinal pigment epithelium against hydroxychloroquine toxicity cAMP-PKA signal pathway. <b>2020</b> , 13, 552-559	1
131	Chloroquine / Hydroxychloroquine: Pharmacological view of an old drug currently used in COVID-19 treatment. 204-215	0
130	The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. <b>2020</b> , 26, 4467-4485	17
129	Dermatologists' Adherence to the Latest Recommendations for Screening of Hydroxychloroquine Retinopathy in Saudi Arabia: Cross-Sectional Study. <b>2019</b> , 8, e15218	2
128	2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus. <b>2020</b> , 1, 5-23	4
127	Chloroquine and Hydroxychloroquine Toxicity. 2, 8	3
126	Hydroxychloroquine Screening Alert: Change is in the Wind. <b>2017</b> , 48, 96-98	7
125	Macular toxicity after short-term hydroxychloroquine therapy. <b>2019</b> , 67, 289-292	13
124	Autoimmune retinopathy associated with systemic lupus erythematosus: A diagnostic dilemma. <b>2017</b> , 7, 172-176	2
123	Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. <b>2019</b> , 8,	25
122	Microperimetry in hydroxychloroquine macular toxicity.. <b>2021</b> , 65, 235-240	1
121	Effects of Hydroxychloroquine on Retinal Vessel Density in Patients with Rheumatoid Arthritis over One-Year Follow-Up: A Pilot Study. <b>2021</b> , 11, 9837	
120	Fundus auto fluorescence and spectral domain ocular coherence tomography in the early detection of chloroquine retinopathy. <b>2015</b> , 74,	

- 119 Therapeutic Drug Monitoring in Rheumatic Diseases. **2016**, 16, 33-37
- 118 Lupus erythematoses. **2017**, 1-18
- 117 Lupus erythematoses. **2018**, 937-953
- 116 Role of optical coherence tomography in the early detection of macular thinning in rheumatoid arthritis patients with chloroquine retinopathy. **2019**, 24, 55 4
- 115 According to the 2019 updated European League Against Rheumatism (EULAR) recommendations for the treatment of systemic lupus erythematosus: debatable issues and comments. **2019**, 57, 496-510 3
- 114 Response to: 'Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus' by Wu. **2020**,
- 113 Drug Safety Issues in Therapy COVID-19. **2020**, 10, 165-187 2
- 112 Antipalúdicos de síntesis en dermatología. **2020**, 54, 1-11
- 111 Use of hydroxychloroquine in dermatology: A multicenter retrospective study in Korea. **2021**, 0
- 110 Drs. Carter and Do reply. **2021**, 48, 151
- 109 Systemic Drugs Used in Dermatology. **2020**, 177-212
- 108 Treating Rheumatoid Arthritis Through the Life Course. **2020**, 185-200
- 107 Animal Models of Diseases of the Retinal Pigment Epithelium. **2020**, 325-347
- 106 Lupus Erythematosus. **2020**, 1-17 1
- 105 Hydroxychloroquine dosing and toxicity: A real-world experience in Saudi Arabia of 63 patients. **2020**, 34, 151-155 2
- 104 Ophthalmic Complications of the Rheumatic Diseases and Anti-Rheumatic Drugs (in Elderly). **2020**, 73-94
- 103 COVID-19 in ophthalmic practice. **2020**, 1
- 102 Adherence to new Royal College of Ophthalmology guidance for hydroxychloroquine retinal screening in rheumatology patients. **2020**, 20, s93-s94

101	Evaluating the Use of Hydroxychloroquine in Treating Patients With Rheumatoid Arthritis. <b>2021</b> , 13, e19308	0
100	A Proposed Aeromedical Disposition Flowchart for Systemic Lupus Erythematosus. <b>2020</b> , 91, 826-832	
99	Retinal Toxicity in Patients Treated With Hydroxychloroquine: A Cross-Sectional Study. <b>2016</b> , 5, 41-46	2
98	Highly Accelerated Onset of Hydroxychloroquine Macular Retinopathy. <b>2017</b> , 17, 280-283	5
97	Hydroxychloroquine in Dermatology and Beyond: Recent Update. <b>2020</b> , 11, 453-464	5
96	Hydroxychloroquine in IgA nephropathy: a systematic review. <b>2021</b> , 43, 1520-1527	0
95	Targeted Delivery of Chloroquine to Antigen-Presenting Cells Enhances Inhibition of the Type I Interferon Response. <b>2021</b> ,	0
94	Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19. <b>2021</b> ,	
93	Risk of hydroxychloroquine retinopathy in the community. <b>2021</b> ,	0
92	A novel 5-ring multifocal electroretinography stimulus for detecting hydroxychloroquine retinal toxicity. <b>2021</b> , 1	
91	Hydroxychloroquine in dermatology and beyond: Recent update. <b>2020</b> , 11, 453	10
90	Systemischer Lupus Erythematos (SLE) (engl. Systemic lupus erythematosus). <b>2021</b> , 803-813	
89	Immunosuppression in Rheumatologic and Auto-immune Disease. <b>2021</b> , 1	1
88	Introduction on therapeutic opportunities for autoimmunity. <b>2022</b> , 1-11	
87	Evaluation of The Role of Spectral-Domain Optical Coherence Tomography in The Early Detection of Macular and Ganglion Cell Complex Thickness Changes in Patients with Rheumatologic Diseases Taking Hydroxychloroquine.. <b>2022</b> , 102741	
86	Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions.. <b>2022</b> , 15, 23	0
85	When should we start screening for hydroxychloroquine retinopathy?. <b>2022</b> ,	
84	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <b>2021</b> ,	4

- 83 Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.. **2022**, 14, 1759720X211073001
- 82 [Translated article] Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19.. **2022**, 113, T166-T175
- 81 RetINal Toxicity And HydroxyChloroquine Therapy (INTACT): protocol for a prospective population-based cohort study.. **2022**, 12, e053852
- 80 Risk of Maculopathy with Pentosan Polysulfate Sodium Use.. **2022**,
- 79 Hydroxychloroquine screening practice: a survey of doctors requesting mfERG testing.. **2022**, ○
- 78 HYDROXYCHLOROQUINE TREATMENT ALTERS RETINAL LAYERS AND CHOROID WITHOUT APPARENT TOXICITY IN OPTICAL COHERENCE TOMOGRAPHY.. **2022**, 102806 1
- 77 Practical management of patients on hydroxychloroquine.. **2021**, 88, 105316 ○
- 76 Effect of Chloroquine and Hydroxychloroquine on Cytokine Release Syndrome in Patients with COVID-19.. **2021**, 19, 179-182 ○
- 75 BRAFV600E-driven lung adenocarcinoma requires copper to sustain autophagic signaling and processing.. **2022**, ○
- 74 Advances in the clinical use of hydroxychloroquine levels.. **2022**, 34, 151-157 ○
- 73 What Have We Learnt About the Treatment of Juvenile-Onset Systemic Lupus Erythematosus Since Development of the SHARE Recommendations 2012?. **2022**, 10, 884634 ○
- 72 Hydroxychloroquine Causes Early Inner Retinal Toxicity and Affects Autophagosome-Lysosomal Pathway and Sphingolipid Metabolism in the Retina.. **2022**, 1 ○
- 71 Image\_1.TIF. **2019**,
- 70 Image\_2.TIF. **2019**,
- 69 Image\_3.TIF. **2019**,
- 68 Image\_4.TIF. **2019**,
- 67 Image\_5.TIF. **2019**,
- 66 Table\_1.xlsx. **2019**,

65	Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19.. <b>2022</b> , 109954	0
64	Lupus Erythematosus. <b>2022</b> , 923-939	
63	Systemic Lupus Erythematosus. <b>2022</b> , 7095-7108	
62	Quantitative autofluorescence findings in patients undergoing hydroxychloroquine treatment.. <b>2022</b> ,	1
61	Safety profile of hydroxychloroquine used off-label for the treatment of patients with COVID-19: A descriptive study based on EudraVigilance data.. <b>2022</b> ,	0
60	Rapid Macular Thinning is an Early Indicator of Hydroxychloroquine Retinal Toxicity.. <b>2022</b> ,	0
59	Drug monitoring in systemic lupus erythematosus.. <b>2022</b> , 64, 102225	
58	Sollte HCQ bei Dialysepflicht bei SLE eingesetzt werden?.	
57	Impact of an Electronic Decision Support Tool to Improve Ophthalmic Safety in Hydroxychloroquine Prescribing Practices. <b>2022</b> , 53, 310-316	
56	MERCI: a machine learning approach to identifying hydroxychloroquine retinopathy using mfERG.	1
55	Automated Machine Learning Detection of Hydroxychloroquine Toxicity and Prediction of Future Toxicity Using Higher Order OCT Biomarkers. <b>2022</b> ,	1
54	Evaluation of Corneal and Retinal Toxicity in Rheumatoid Arthritis Patients Treated with Hydroxychloroquine.	
53	Approach to inherited retinal diseases. <b>2022</b> , 70, 2305	
52	Outcomes of screening for hydroxychloroquine retinopathy at the Manchester Royal Eye Hospital: 2 years audit.	
51	Screening for Plaquenil. <b>2022</b> ,	
50	Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre. 09612033221156	0
49	Nanomedicine platform for targeting activated neutrophils and neutrophil-platelet complexes using an $\alpha$ -antitrypsin-derived peptide motif.	3
48	Selective Detection of Chloroquine in Human Urine with Application at the Point-of-Care.	0

47	Clock-hour topography and extent of outer retinal damage in hydroxychloroquine retinopathy. <b>2022</b> , 12,	
46	Recommendations for Systemic Lupus Erythematosus. <b>2022</b> ,	1
45	Unusual Presentation of Acute Hydroxychloroquine Retinopathy. 1-4	0
44	Extreme Interocular Asymmetry in an Atypical Case of a Hydroxychloroquine-Related Retinopathy. <b>2022</b> , 58, 967	0
43	Compliance With Hydroxychloroquine Screening Guidelines at a Large Academic Medical Center. 247412642210978	
42	How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.	0
41	Choriocapillaris Flow Deficits Quantification in Hydroxychloroquine Retinopathy Using Swept-Source Optical Coherence Tomography Angiography. <b>2022</b> , 12, 1445	0
40	Retinal Toxicity from Chronic Hydroxychloroquine use in Kenya. <b>2022</b> , 21, 301	0
39	Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.	0
38	Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment.	0
37	Subclinical Retinal Capillary Abnormalities in Juvenile Systemic Lupus Erythematosus without Ocular Involvement. 1-9	0
36	Choroidal vascularity index in hydroxychloroquine toxic retinopathy: a quantitative comparative analysis using enhanced depth imaging in spectral domain optical coherence tomography. <b>2022</b> , Publish Ahead of Print,	0
35	Characteristics and Potential Risk Factors of Hydroxychloroquine Retinopathy in Patients with Systemic Lupus Erythematosus: Focusing on Asian Population.	0
34	Novel imaging techniques for hydroxychloroquine retinopathy. 9,	0
33	Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches. 9,	0
32	Non-leaking cystoid macular edema and bull's eye maculopathy caused by hydroxychloroquine toxicity in Asian patients. <b>2022</b> , 5, 17-21	0
31	Documento de consenso del Grupo de Estudio de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN) para el diagnóstico y tratamiento de la nefritis lúpica. <b>2022</b> ,	0
30	Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report. <b>2022</b> , 22,	0



- 29 The Association of Hydroxychloroquine Dosing with Adverse Cardiac Events in Patients with Systemic Lupus Erythematosus. ○
- 28 A nationwide survey of hydroxychloroquine retinopathy presenting to the hospital eye service in the United Kingdom. ○
- 27 Hydroxychloroquine dose: balancing toxicity and SLE flare risk. ○
- 26 Knowledge of Saudi Patients with Autoimmune Diseases about Hydroxychloroquine Toxicity: The Role of Physician-Patient Communication. **2022**, 10, 152 ○
- 25 Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine. **2022**, 9, e000789 ○
- 24 Initial trial of an electronic dashboard to improve dosing of hydroxychloroquine within the VA healthcare system: Time series analysis (Preprint). ○
- 23 Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer. **2022**, 14, 2551 ○
- 22 Hypertension related toxicity of chloroquine explains its failure against COVID-19: Based on rat model. 13, ○
- 21 Probing the neuro-psychological changes observed with the administration of COVID-19 Drugs. **2022**, 23, 1
- 20 Skin and ophthalmic complications of chloroquine and hydroxychloroquine in patients with rheumatoid arthritis and systemic lupus erythematosus. ○
- 19 Hydroxychloroquine Dose and Risk for Incident Retinopathy. ○
- 18 Bewertung von Wechselwirkungen und Dosierungsempfehlungen von synthetischen DMARDs □ Evidenz- und konsensbasierte Empfehlungen auf Basis einer systematischen Literatursuche. ○
- 17 Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus. **2023**, 10, e000841 ○
- 16 Initial trial of an electronic dashboard to improve dosing of hydroxychloroquine within the VA healthcare system: Time series analysis (Preprint). ○
- 15 Systemic Lupus Erythematosus. **2023**, 167-212 ○
- 14 Adverse effects of hydroxychloroquine use in patients with cicatricial alopecia: A systematic review. ○
- 13 Screening for toxic retinopathy due to antimalarial drugs in Tunisia. **2023**, 46, 356-362 ○
- 12 Hydroxychloroquine Therapy in Sarcoidosis-Associated Uveitis. 1-7 ○

- 11 Systemic Lupus Erythematosus May Be a Risk Factor for Antimalarial-Induced Retinopathy Compared With Other Rheumatologic Diseases. **2023**, 5, 173-179 ○
- 10 Prevalence and Risk Factors of Hydroxychloroquine Retinopathy in Rheumatic Patients with Dry Eye Symptoms. **2023**, 64, 123-131 ○
- 9 Adverse Ocular Effects of Systemic Medications. **2023**, 13, 660 ○
- 8 Hydroxychloroquine Dose and Risk of Systemic Lupus Erythematosus FlaresReply. **2023**, 329, 686 ○
- 7 Treatment of lupus nephritis: consensus, evidence and perspectives. **2023**, 19, 227-238 ○
- 6 Application of optical coherence tomography angiography for microvascular changes in patients treated with hydroxychloroquine: a systematic review and meta-analysis. ○
- 5 Foveal photoreceptor disruption in ocular diseases: An optical coherence tomography-based differential diagnosis. **2023**, ○
- 4 Low estimated glomerular filtration rate is an independent risk factor for higher hydroxychloroquine concentration. ○
- 3 The Impact of Systemic Medications on Retinal Function. **2023**, 12, 115-157 ○
- 2 Lupus Nephritis. **2023**, 737-763 ○
- 1 Les intelligences artificielles conversationnelles en médecine interne : l'exemple de l'hydroxychloroquine selon ChatGPT. **2023**, ○